United States - English - NLM (National Library of Medicine)

warner chilcott pharmaceuticals inc. - risedronate sodium (unii: ofg5exg60l) (risedronic acid - unii:km2z91756z) - risedronate sodium 150 mg - actonel is indicated for the treatment and prevention of osteoporosis in postmenopausal women. in postmenopausal women with osteoporosis, actonel reduces the incidence of vertebral fractures and a composite endpoint of nonvertebral osteoporosis-related fractures [see clinical studies (14.1, 14.2) ]. actonel is indicated for treatment to increase bone mass in men with osteoporosis. actonel is indicated for the treatment and prevention of glucocorticoid-induced osteoporosis in men and women who are either initiating or continuing systemic glucocorticoid treatment (daily dosage of ≥ 7.5 mg prednisone or equivalent) for chronic diseases. patients treated with glucocorticoids should receive adequate amounts of calcium and vitamin d. actonel is indicated for treatment of paget’s disease of bone in men and women. - abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia [see warnings and precautions (5.1) ] - inability to stand or sit upright for at least 30 minutes [see dosage

European Union - English - EMA (European Medicines Agency)

warner chilcott uk ltd. - testosterone - sexual dysfunctions, psychological - sex hormones and modulators of the genital system, - intrinsa is indicated for the treatment of hypoactive sexual desire disorder (hsdd) in bilaterally oophorectomised and hysterectomised (surgically induced menopause) women receiving concomitant estrogen therapy.

European Union - English - EMA (European Medicines Agency)

warner chilcott  deutschland gmbh - testosterone - sexual dysfunctions, psychological - sex hormones and modulators of the genital system, - livensa is indicated for the treatment of hypoactive sexual desire disorder (hsdd) in bilaterally oophorectomised and hysterectomised (surgically induced menopause) women receiving concomitant estrogen therapy.

United States - English - NLM (National Library of Medicine)

liberty pharmaceuticals, inc. - bupropion hydrochloride (unii: zg7e5poy8o) (bupropion - unii:01zg3tpx31) - bupropion hydrochloride 150 mg - bupropion hydrochloride extended-release tablets, usp (sr) are indicated for the treatment of major depressive disorder. the efficacy of bupropion in the treatment of a major depressive episode was established in two 4-week controlled trials of depressed inpatients and in one 6-week controlled trial of depressed outpatients whose diagnoses corresponded most closely to the major depression category of the apa diagnostic and statistical manual (dsm) (see clinical pharmacology). a major depressive episode (dsm-iv) implies the presence of 1) depressed mood or 2) loss of interest or pleasure; in addition, at least 5 of the following symptoms have been present during the same 2-week period and represent a change from previous functioning: depressed mood, markedly diminished interest or pleasure in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentrati

United States - English - NLM (National Library of Medicine)

warner chilcott (us), inc. - doxycycline hyclate (unii: 19xts3t51u) (doxycycline - unii:n12000u13o) - capsule, delayed release pellets - 100 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of doryx and other antibacterial drugs, doryx should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. doxycycline is indicated for the treatment of the following infections: doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriological testing indicates appropri

United States - English - NLM (National Library of Medicine)

ncs healthcare of ky, inc dba vangard labs - bupropion hydrochloride (unii: zg7e5poy8o) (bupropion - unii:01zg3tpx31) - bupropion hydrochloride 150 mg - major depressive disorder: bupropion hydrochloride extended-release tablets (xl) are indicated for the treatment of major depressive disorder. the efficacy of bupropion in the treatment of a major depressive episode was established in two 4-week controlled trials of inpatients and in one 6-week controlled trial of outpatients whose diagnoses corresponded most closely to the major depression category of the apa diagnostic and statistical manual (dsm) (see clinical trials). a major depressive episode (dsm-iv) implies the presence of 1) depressed mood or 2) loss of interest or pleasure; in addition, at least 5 of the following symptoms have been present during the same 2-week period and represent a change from previous functioning: depressed mood, markedly diminished interest or pleasure in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration,

United States - English - NLM (National Library of Medicine)

anchen pharmaceuticals, inc. - bupropion hydrochloride (unii: zg7e5poy8o) (bupropion - unii:01zg3tpx31) - bupropion hydrochloride 150 mg - bupropion hydrochloride extended-release tablets (sr) are indicated as an aid to smoking cessation treatment. bupropion hydrochloride extended-release tablets (sr) are contraindicated in patients with a seizure disorder. bupropion hydrochloride extended-release tablets (sr) are contraindicated in patients treated with wellbutrin (bupropion hydrochloride), the immediate-release formulation; wellbutrin sr (bupropion hydrochloride), the sustained-release formulation; wellbutrin xl (bupropion hydrochloride), the extended-release formulation; or any other medications that contain bupropion because the incidence of seizure is dose dependent. bupropion hydrochloride extended-release tablets (sr) are contraindicated in patients with a current or prior diagnosis of bulimia or anorexia nervosa because of a higher incidence of seizures noted in patients treated for bulimia with the immediate-release formulation of bupropion. bupropion hydrochloride extended-release tablets (sr) are contraindicated in patients undergoing

Ireland - English - HPRA (Health Products Regulatory Authority)

warner chilcott uk limited - risedronate sodium - film coated tablet - 5 milligram - bisphosphonates

Ireland - English - HPRA (Health Products Regulatory Authority)

warner chilcott uk limited - risedronate sodium - film coated tablet - 30 milligram - bisphosphonates

Ireland - English - HPRA (Health Products Regulatory Authority)

warner chilcott uk limited - risedronate sodium - film coated tablet - 75 milligram - bisphosphonates